In Chinese patients with type 2 diabetes, more patients reached HbA1c <7.0% without weight gain or hypoglycemia at week 26 with dulaglutide 1.5 mg (40-48%) than with the active comparators glimepiride or insulin glargine (15-20%).
In plain wordsIn Chinese patients with diabetes, more reached the combined target with dulaglutide 1.5 mg than with glimepiride or insulin glargine at week 26.
- Peptide
- Dulaglutide (Trulicity)
- Outcome
- IncreasePrimary composite at week 26
- Study
n: not reported in source
- Comparator
- Active comparators (glimepiride or insulin glargine, by trial)
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1.5 mg · 26 weeksAs given in this study (human).
Measurements
- Composite attainment
- 40 to 48%
- dulaglutide 1.5 mg, range across the two trials
- Composite attainment
- 15 to 20%
- active comparators (glimepiride or insulin glargine), range across the two trials
Source sentences
In each analyzed trial, 40-48% of patients received DU (1.5 mg), 30-39% of patients received DU (0.75 mg) and 15-20% of patients on active comparators (GLIM/GLAR) reached the primary composite end-point at week 26 (P < 0.001 for DU vs GLIM/GLAR).
4 context sentences(design, population, supporting numbers)
To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite end-point in Chinese type 2 diabetes patients.
Post-hoc analyses of two randomized phase III trials (NCT01644500 and NCT01648582) were carried out using Fisher's exact test.
The primary composite end-point was the number of patients reaching glycated hemoglobin (HbA1c) <7.0%, without weight gain and hypoglycemia.
Secondary composite end-points included the number of patients reaching HbA1c <7.0% without weight gain and HbA1c <7.0% without hypoglycemia.